Modeling Study Published in Clinical Gastroenterology and Hepatology Validates Geneoscopy's ColoSense® Real-World Screening Impact
ST. LOUIS--(BUSINESS WIRE)--Jun 24, 2025--
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the publication of a new study in Clinical Gastroenterology and Hepatology showing that its FDA-approved multitarget stool RNA (mt-sRNA) test, ColoSense®, achieved notable clinical benefits among colorectal cancer (CRC) screening tests when modeled at real-world adherence levels.
In the absence of a head-to-head study comparing CRC screening options, this peer-reviewed modeling study, titled 'Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia,' provides valuable insights by evaluating five CRC screening strategies for patients aged 45 and older. Using a 10-year Markov model, researchers simulated disease progression, comparing mt-sRNA, two mt-sDNA tests, a blood-based test, and a fecal immunochemical test (FIT), and reported findings similar to previously published modeling studies. 1-3 When test performance was normalized to better reflect the age of the intended use population, the clinical and economic benefits of ColoSense were amplified.
At real-world adherence of 60% (the typical rate observed in practice), the modeling study results showed that ColoSense reduced CRC deaths by 14% compared to FIT, by 19% and 23% compared to the mt-sDNA tests, and by 86% compared to a blood-based test. 1 While FIT remained the most cost-effective strategy overall, ColoSense was the most cost-effective among molecular tests across all levels of screening adherence.
'Study cohorts often don't reflect the target patient population, which can skew results and limit clinical relevance,' said Dr. Erica Barnell, co-author and Chief Science and Medical Officer at Geneoscopy. 'These data reinforce the need to design studies around real-world populations. ColoSense was developed with that in mind, delivering strong performance across diverse groups, including younger adults who are often under-represented in clinical trials.'
This study builds on prior research by using a model that normalizes the age of the populations in independent, peer-reviewed studies to better reflect the general screening population. Given that many assays rely on methylation-based biomarkers, whose sensitivity is lower in younger individuals, 4,5 adjusting sensitivity estimates for colorectal cancer and advanced adenomas is essential for accurate clinical and economic assessment.
ColoSense is included in the 2025 National Comprehensive Cancer Network (NCCN) guideline update, highlighting the strength of its clinical evidence and the robust science behind Geneoscopy's RNA-based approach. As the only FDA-approved stool RNA test for CRC screening, ColoSense represents a significant step forward in noninvasive screening methods, underscoring the need for accessible alternatives that can increase compliance, especially among groups less likely to pursue colonoscopy.
*All data used in the study were derived from independent, non-head-to-head clinical trial results.
About ColoSense
ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.
A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA) in October 2023. For more information, visit www.colosense.com.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
References
View source version on businesswire.com:https://www.businesswire.com/news/home/20250624950274/en/
CONTACT: Media Contact
Andrea Sampson
Sampson Public Relations Group
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MISSOURI
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH MANAGED CARE ONCOLOGY HEALTH GENETICS CLINICAL TRIALS
SOURCE: Geneoscopy, Inc.
Copyright Business Wire 2025.
PUB: 06/24/2025 08:05 AM/DISC: 06/24/2025 08:04 AM
http://www.businesswire.com/news/home/20250624950274/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Aledade Acquires More Michigan Value-Based Care Operations
BETHESDA, Md.--(BUSINESS WIRE)-- Aledade, the nation's largest network of independent primary care, today announced its acquisition of the Michigan-based value-based care operations of CCA Holding Company, Inc. 'This move further expands value-based care in Michigan, empowering more independent primary care organizations to continue providing high quality care in communities they serve," said Ahmed Haque, chief performance officer at Aledade. This acquisition includes an Accountable Care Organization (ACO) and Physician Organization operating in Southeast Michigan and all related employees, further expanding Aledade's existing expertise and presence across the state. Aledade currently supports more than 1,500 physician partners across more than 180 primary care practices and community health centers statewide, reflecting additional growth including last year's acquisition of Medical Advantage, a Michigan-based provider of practice performance improvement and value-based care enablement solutions. 'We are excited to welcome these physician-led organizations into Aledade,' said Ahmed Haque, chief performance officer at Aledade. 'This move further expands value-based care in Michigan, empowering more independent primary care organizations to continue providing high quality care in communities they serve.' In the 2023 Medicare Shared Savings Program (MSSP) performance year, Aledade ACOs generated a record $801 million in savings, surpassing all other accountable care partners nationwide, and achieved quality scores higher than average non-Aledade MSSP participants. Aledade's physician-led ACOs were among the top performers in MSSP, with 93% achieving savings compared to under 70% among non-Aledade participants. Since 2014, Aledade and its partners have saved more than $2 billion in health care for U.S. taxpayers. 'As part of Aledade, the value-based care operations of CCA Holding Company, Inc. will have the ideal platform to continue successfully serving over 500 independent primary care and specialty offices in Southeast Michigan,' said David Klein, Chair of the CCA Holding Company, Inc. About Aledade Aledade, a public benefit corporation, is the largest network of independent primary care in the country, helping independent practices, health centers and clinics deliver better care to their patients and thrive in value-based care. Through its proven, scalable model, which includes cutting-edge data analytics, user-friendly guided workflows, health care policy expertise, strong payer relationships and integrated care solutions, Aledade empowers physicians to succeed financially by keeping people healthy. Together with more than 2,400 practices, federally-qualified health centers and community health centers in 46 states and the District of Columbia, Aledade shares in the risk and reward across more than 200 value-based contracts representing nearly 3.0 million patient lives under management. To learn more, visit or follow on X (Twitter), Facebook or LinkedIn.
Yahoo
an hour ago
- Yahoo
Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting
WOODBRIDGE, Conn., June 24, 2025--(BUSINESS WIRE)--Cure Rare Disease (CRD), a nonprofit biotechnology organization developing genetic therapies for ultra-rare diseases, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy program for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMDR9). The LGMDR9 program, known as CRD-003, utilizes a novel, liver de-targeting, muscle tropic capsid - developed by the Grimm Lab at University of Heidelberg - to deliver a functional copy of the FKRP gene. Murine and non-human primate studies support that AAVMYO2 de-targets the liver while offering enhanced muscle tropism which allows for a reduction of the clinical dose. CRD-003 is designed for patients with LGMDR9 caused by mutations in the FKRP gene, a condition that leads to progressive muscle weakness and loss of ambulation. CRD-003 is intended to be administered as a single intravenous injection and is among the first gene therapy candidates tailored to this rare neuromuscular disease population using a next-generation AAV capsid. Following the pre-IND interaction, the FDA provided written feedback across key domains including Chemistry, Manufacturing, and Controls (CMC), nonclinical development, and clinical trial design. The agency supported CRD's overall development approach while offering constructive guidance to further strengthen the planned Investigational New Drug (IND) submission. Notably: The FDA agreed that a 4-month murine GLP toxicology study, incorporating acute and chronic toxicity assessments, could be sufficient to support initiation of the first-in-human trial. The agency endorsed the proposed clinical trial design and patient selection strategy, and deemed the biomarker strategy—evaluating glycosylation changes and muscle MRI—appropriate. The agency suggested that CRD-003 may seek accelerated approval on the basis of results from the Phase I/II clinical trial, pending results "Receiving FDA feedback is a critical milestone as we advance CRD-003 toward the clinic," said Rich Horgan, Founder and CEO of Cure Rare Disease. "Early and proactive engagement with the FDA is a cornerstone of our drug development strategy. It ensures that our programs are aligned with regulatory expectations from the outset, allowing us to prioritize both patient safety and operational efficiency. This collaborative dialogue helps us navigate the complexities of developing therapies for rare diseases while furthering our ability to bring much-needed treatments to the individuals who need them most." With this milestone completed, CRD will continue executing its IND-enabling studies, incorporating FDA recommendations, and preparing for IND submission. About Cure Rare DiseaseCure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Woodbridge, CT, is transforming possibilities for people with ultra-rare diseases by developing advanced therapeutics in time to save lives. Through a collaborative community of forward-thinking families, patients, scientists and supporters, Cure Rare Disease has enabled an ecosystem of innovation and discovery to overcome the obstacles inherent in existing models of medicine and to expedite life-saving genetic technologies from research to the clinic. For more information, please visit View source version on Contacts Media Contact: Ahna GavrelosDirector of Marketing CommunicationsCure Rare DiseaseEmail: media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
LifeMD, Inc. (NASDAQ:LFMD) Could Be Less Than A Year Away From Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at LifeMD, Inc.'s () future prospects. LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. With the latest financial year loss of US$22m and a trailing-twelve-month loss of US$14m, the US$650m market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which LifeMD will turn a profit, with the big question being 'when will the company breakeven?' In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. LifeMD is bordering on breakeven, according to the 7 American Healthcare Services analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$2.3m in 2025. The company is therefore projected to breakeven around 12 months from now or less. How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 105% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Given this is a high-level overview, we won't go into details of LifeMD's upcoming projects, though, bear in mind that by and large healthcare tech companies, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. See our latest analysis for LifeMD Before we wrap up, there's one issue worth mentioning. LifeMD currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag. There are too many aspects of LifeMD to cover in one brief article, but the key fundamentals for the company can all be found in one place – LifeMD's company page on Simply Wall St. We've also compiled a list of relevant aspects you should look at: Valuation: What is LifeMD worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether LifeMD is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on LifeMD's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
